can allow for the efficient, painless delivery of medications that may reduce systemic side effects associated with the medication while providing clinical advantages over injected or oral administration for the same clinical situation.[12]
The present clinical study was planned to study the efficacy and safety of Arthrella ointment in the symptomatic alleviation of acute and chronic inflammatory Osteoarthritis pain. The result showed better WOMAC and VAS scores after 4 weeks along with statistically significant difference in the relief of pain in the two groups. This effect increased regularly over the whole study period. There were no adverse reactions attributed to the Arthrella ointment.
These excellent beneficial actions of Arthrella ointment are because of its potent topical anti-inflammatory, analgesic and counter-irritant properties. Cinnamomum camphora, Oils of Gaultheria fragrantissima & Capsicum annum are counter-irritants and helps to relieve pain immediately. Eucalyptus globulus,[13,15] Vitex negundo are analgesic, anti-inflammatory medicines. [17] Arthrella ointment targets the peripheral nerves and soft tissue at pain site. The counter-irritants in Arthrella ointment also help the absorption of the anti-inflammatory ingredients through the skin. Thus, Arthrella ointment relieves pain immediately, reduces inflammation rapidly and restores mobility instantly.
Conclusion
In conclusion, this trial demonstrates the potential efficacy and safety of Arthrella ointment in the symptomatic treatment of OA pain over 4 weeks of therapy. The Arthrella ointment demonstrated better results with acute and chronic inflammatory pain experienced in chronic degenerative condition like osteoarthritis.
References
1. Felson DT. Epidemiology of hip and knee osteoartritis. Epidemiol Rev 1988;10: 1-28.
2. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60: 91-7.
3. Yelin E. The earnings, income, and assets of
persons aged 51-61 with and without musculoskeletal conditions. J Rheumatol 1997;24: 2024-30.
4. Wynne HA, Campell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmacoeconomics 1994;3: 107-23.
5. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95: 1681-90.
6. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8: 18-24.
7. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123: 241-9.
8. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998;51(suppl): 8-16.
9. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325: 624-7.
10. Trolamine salycylate cream in osteoarthritis of the knee. JAMA 1982;247: 1311-3.
11. Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions - a review of the literature. Drugs 1998;56: 783-99.
12. Stephani Schmidt, MSc (Pharm), Topical treatments for musculoskeletal pain., SA Pharmacist’s Assistant [Winter 2016]
13. Tomohiko Kotaka, Shoji Kimura, Makoto Kashiwayanagi, Jun Iwamoto., Camphor induces cold and warm sensations with increases in skin and muscle blood flow in human., Biol Pharm Bull., 2014;37(12)